The introduction of clozapine in the 1980’s suggested a potential that other brain targets might complement the blockade of dopamine D2 receptors to treat symptoms that failed to respond to the “typical” antipsychotics. We are now entering an age where new treatments are being rationally developed within the context of translational neuroscience, i.e., the steps whereby basic molecular neuroscience leads to fundamental new mechanisms that can be tested in animal and human laboratory-based research that, in turn, leads to tests of new medications in our clinics. The January 1st issue of Biological Psychiatry includes encouraging new research related to three new treatment approaches.
In the first study, Olszewski and colleagues tested a novel drug that inhibits the breakdown of the transmitter N-acetylaspartylglutamate (NAAG), which activates a receptor that reduces schizophrenia-like behaviors in some animal models. Their findings indicate that this drug is effective in an animal model of schizophrenia. Joseph H. Neale, Ph.D., lead author on this project, comments, “While treating patients with receptor agonists can be highly effective therapy, drugs that increase the action of the transmitter that activates the same receptor have traditionally been very effective with fewer side effects than chronic agonist treatment.” He adds, “These data support the conclusion that NAAG peptidase inhibitors represent a breakthrough in the discovery of a completely novel means of adjunct therapy for schizophrenia that is analogous to the use of SSRIs [selective serotonin reuptake inhibitors] for the treatment of depression."
In the second article, Hashimoto and colleagues demonstrated that repeated administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP) decreased the density of ?7 nicotinic receptors (?7 nAChRs) in the mouse brain, and that the novel ?7 nAChR agonist SSR180711 could ameliorate PCP-induced cognitive deficits in mice. According to Kenji Hashimoto, Ph.D., head author for this study, the impetus for this study came from the fact that “accumulating evidence suggests that ?7 nicotinic receptors, a subtype of nicotinic receptors, are a most attractive target for novel therapeutic drugs of neuropsychiatric diseases including schizophrenia and Alzheimer’s disease. Behavioral abnormalities in animals after repeated administration of the NMDA receptor antagonist phencyclidine (PCP) have been used an animal model of schizophrenia.” These findings suggest that ?7 nAChR agonists including SSR180711 could be potential therapeutic drugs for cognitive deficits in schizophrenic patients.
In the third investigation, Semenova and colleagues show that a recently discovered brain receptor for serotonin (5-HT7) might be of importance for understanding certain aspects of schizophrenia. Their study focused on sensory input processing, which is often impaired in schizophrenia, and finds that blockade of this particular serotonin receptor in mice alleviates this impairment. Peter B. Hedlund, M.D., Ph.D., senior author, notes: “Certain pharmaceuticals used to treat schizophrenia interact with this receptor. Our results indicate that especially so-called atypical antipsychotics may promiscuously exert some of their beneficial effects through the 5-HT7 receptor. Further exploration of this receptor as a treatment target may lead to more specific and better medications for disorders such as schizophrenia.”
John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, “It is very clear that very few tested medications actually become new treatments. However, the embedding of clinical research within the framework of translational neuroscience increases the likelihood that one or another of these mechanisms might someday emerge as a treatment for schizophrenia.” Dr. Krystal concludes, “Since we have so few mechanistically distinct approaches for the pharmacotherapy of schizophrenia, the possibility of the emergence of new treatment mechanisms is certainly a source of hope.”
Jayne Dawkins | alfa
'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine
Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.
But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...
Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.
The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...
Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters
Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
21.02.2018 | Life Sciences
21.02.2018 | Life Sciences
21.02.2018 | Materials Sciences